Skip to main content
. 2018 Dec 11;8(12):125. doi: 10.1038/s41408-018-0163-7

Fig. 3. Overall survival by induction treatment regimen.

Fig. 3

4-year overall survival rates with immunomodulatory drug–proteasome inhibitor combination (n = 145; blue curve), proteasome inhibitor–alkylator combination (n = 160; green curve), and a doublet regimen (n = 192; red curve) were similar, 80.6%, 79.9%, and 83.6%, respectively, P = 0.67